pocketful logo
Morepen Laboratories Ltd logo

Morepen Laboratories Ltd

NSE: MOREPENLAB BSE: 500288

₹43.67

(-2.19%)

Wed, 04 Mar 2026, 11:54 pm

mtf coin illustrationMTF 5x

Company History

1984

  • Morepen Laboratories Limited Company was incorporated on December 1st.

1992

  • The Company was converted into a Public Limited Company on March 16.
  • 34,00,000 equity shares were issued at a premium of Rs 15 per share.

1993

  • The Company adapted technology from M/s. Techquin Elabeissment, Switzerland.
  • Morepen set up a formulations division.
  • The Company undertook to establish facilities for herbal research and development at Gurgaon.
  • 18,00,000 shares were issued, subscribed, and paid up.

1995

  • The Company launched high-value high-technology products, namely Cisapride and Loratadine.
  • 26,00,000 shares were allotted on conversion of 'O' interest debentures.

1996

  • 78,00,000 shares were allotted on a Rights basis.

1997

  • Morepen was close to entering into a tie-up with Stryker Corporation.
  • The Company planned to launch its OTC healthcare product range.
  • Morepen introduced garlic-based tablets, ginger-based tablets, and other products.

1998

  • Morepen signed agreements with European generic companies to import bulk drugs.
  • The Company expanded its marketing network for exports.
  • Morepen introduced Loratadine and Cisapride in bulk and formulation forms.
  • The Company made its entry into the US market with the filing of a drug master file for loratadine.

1999

  • Morepen signed an agreement with PARI GmbH for marketing inhalation systems.
  • The Company became the youngest Indian company to obtain USFDA approval.
  • Morepen's manufacturing facilities for Loratadine were awarded USFDA approval.
  • The Company launched DAB, an antacid with fruit flavors.
  • Morepen set up a state-of-the-art plant at Baddi in Himachal Pradesh.
  • The Company introduced Dab, an ayurvedic antacid granule.
  • Morepen planned to introduce vitamin products for pregnant women.
  • The Company entered into the segment of generic manufacturing.
  • Morepen identified 20 non-patent high-volume generic products.
  • The Company planned to launch new products, including Atorvastatin and Fluvastatin.

2000

  • The Company allotted 25,00,000 equity shares on a preferential allotment basis.
  • Morepen decided to split its equity shares and formed a compensation committee.
  • The Company entered into a joint venture agreement for research and development in medicinal biotechnology.
  • Morepen tied up with generic companies in Canada for supplying loratadine.
  • Shri. K. B. Suri, Chairman cum Managing Director, expired and Shri Sushil Suri was appointed as Chairman cum Managing Director.

2001

  • DiaMed AG formed a technology-cum-marketing joint venture with Morepen Laboratories.
  • Morepen launched Optimal Rapid Malaria Test Kit.
  • The Company reissued 17,000 equity shares to its employees.
  • Morepen entered into a strategic manufacturing joint venture with Ameritek Inc.
  • The Company entered into a marketing alliance with Beurer GmbH & Co.

2002

  • Apollo Hospitals Group and Morepen Laboratories entered into a joint venture for emergency services.
  • The Company decided not to buy Coldact from Sun Pharmaceuticals.
  • Morepen launched 'Dab' in the gastro category.
  • The Company invested Rs. 100cr to achieve sales of Rs. 200cr in five years.
  • Morepen created four SBUs via global generics, medicus, diagnostics, and fast-moving health goods.
  • Mr. Vasanth Sivaraman was appointed as Vice-president, corporate finance.
  • The Company acquired Lifespring, a chain of health and beauty stores.
  • Morepen acquired Lemolate, a premium brand in the cough and cold category.
  • The Company hiked its expenditure for R&D initiatives.
  • Morepen increased its production capacity for loratidine.
  • Mr. Sanjay Suri was appointed as Director on the Board.
  • The Company signed a marketing joint venture with Italian Diagnostic company A Menarini.
  • The USFDA approved Loratadine as an Over-the-counter Allergy Drug.
  • Morepen invested Rs. 12 cr in Lifespring.
  • Mr. Karthik Raina quit Morepen Laboratories.

2003

  • Morepen tied up with Analyticon to market urine analysis reagent strips.
  • The Company got 180-day marketing rights for a drug in the US market.
  • Morepen filed an international patent under the Patent Cooperation Treaty for the manufacturing process of Desloratadine.
  • Mr. Sanjay Suri and Ms. Kanta Suri resigned from their directorship of the company.
  • The Board of Directors approved the GDR issue.
  • Morepen signed an agreement for a collaborative research program with the National Institute of Pharmaceutical Education and Research.
  • The Company received clearance from the Luxembourg Stock Exchange for its GDR offering.
  • Morepen allotted 5,000,000 GDRs representing 50,000,000 equity shares.
  • The Debt Recovery Tribunal put a hold on the proceedings of the lab's $15.25 million GDR issue.
  • The Company extended its financial year by 6 months.
  • Morepen applied for international process and product patents for Fluvastatin Sodium.
  • The CLB approved the Company's fixed deposits repayment plan.
  • Morepen accomplished an export order of Loratadine for $15 million.
  • The Company bagged a 15-year supply contract and licensing agreement from Generix.
  • Morepen received US Food and Drug Administrator approval for its API manufacturing facilities at Masulkhana, Himachal Pradesh.

2004

  • Morepen Labs received approval for an international patent for a new crystalline form of Atorvastatin.
  • The Company received a fresh US Food and Drug Administrator approval for its API manufacturing facilities at Masulkhana, Himachal Pradesh.
  • Morepen entered the anti-diabetics market in the US with its insulin sensitizer Pioglitazone Hydrochloride (Actos).
  • Morepen Labs bagged an international patent for a cholesterol drug.

2005

  • Morepen Laboratories became the second company to join the Lipitor Club in the USA.
  • Morepen announced 52 DMF filings for 6 products in the EU.
  • Morepen registered 52 DMF across 10 European countries.
  • The Company increased its holding in Doctors Morepen Ltd (DML).

2006

  • Mr. Manoj Joshi and Mr. B R Wadhwa were re-appointed as Directors of the Company.

2007

  • Morepen Lab signed a deal with Avenue Capital Group.

2011

  • Morepen received USFDA approval for Desloratadine.

2013

  • Mr. Thomas P. Joshua joined as the Company's Company Secretary and Compliance Officer.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800